CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Ivermectin Oral ProductWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug152 Aluminum hydroxide Wiki 0.71
drug2126 SARS-CoV Wiki 0.71
drug1822 Placebo Wiki 0.08

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Cali, Colombia With Early Stages of SARS COV2 / COVID-19

Double blind, placebo controlled, randomized clinical trial to evaluate the efficacy of ivermectin in preventing progression of disease in adult patients with early stages of COVID-19

NCT04405843 COVID-19 Drug: Ivermectin Oral Product Drug: Placebo

Primary Outcomes

Description: Time until deterioration of 2 or more points in an ordinal 7 points scale.

Measure: Time to event

Time: 21 days

Secondary Outcomes

Description: Clinical condition in an ordinal scale of 7 points, on day 2. Higher scores indicate worse outcomes

Measure: Clinical condition on day 2

Time: On day 2 (± 1 day) after randomization

Description: Clinical condition in an ordinal scale of 7 points, on day 5. Higher scores indicate worse outcomes

Measure: Clinical condition on day 5

Time: On day 5 (± 1 day) after randomization

Description: Clinical condition in an ordinal scale of 7 points, on day 8. Higher scores indicate worse outcomes

Measure: Clinical condition on day 8

Time: On day 8 (± 1 day) after randomization

Description: Clinical condition in an ordinal scale of 7 points, on day 11. Higher scores indicate worse outcomes

Measure: Clinical condition on day 11

Time: On day 11 (± 1 day) after randomization

Description: Clinical condition in an ordinal scale of 7 points, on day 15. Higher scores indicate worse outcomes

Measure: Clinical condition on day 15

Time: On day 15 (± 1 day) after randomization

Description: Clinical condition in an ordinal scale of 7 points, on day 21. Higher scores indicate worse outcomes

Measure: Clinical condition on day 21

Time: On day 21 (± 1 day) after randomization

Description: Proportion of subjects who require hospitalization, use of supplementary oxygen for >24 hours or ICU admission

Measure: Proportion of subjects with additional care

Time: 21 days

Description: Proportion of subjects who die

Measure: Proportion of subjects who die

Time: From randomization up to 21 days

Description: Duration of supplementary oxygen, hospitalization, ICU stay

Measure: Duration of additional care

Time: 21 days

Description: Proportion of subjects who develop solicited adverse events

Measure: Adverse events

Time: 21 days

Description: Proportion of subjects who required discontinuation of the trial due to adverse events

Measure: Proportion of subjects who discontinue intervention

Time: 21 days

2 Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled Trial

Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested. In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding among mild to moderate COVID-19 patients, and in shortening the symptom resolution time.

NCT04429711 COVID-19 Drug: Ivermectin Oral Product

Primary Outcomes

Description: The primary outcome will be the viral clearance at day 6 in the intervention group compared to placebo.

Measure: Viral clearance at day 6

Time: Outcome will be determined till 6 days post intervention

Description: Secondary outcomes: viral shedding duration (time between first positive PCR to last of two consecutive negative tests)

Measure: Viral shedding duration

Time: Outcome will be determined till 14 days post intervention

Description: Time between drug treatment and symptoms resolution

Measure: Symptoms clearance time

Time: Outcome will be determined till 14 days post intervention

No related HPO nodes (Using clinical trials)